All In Biotech

Drug Trial Radar · NCT06830863

A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

A Phase 1/2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety, Bioavailability, and Effect of Topically Administered ATR04-484 for Moderate to Severe EGFRi-Associated Dermal Toxicity

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Aug 25, 2025

Primary completion

Jul 15, 2027

Study completion Sep 15, 2027

Sponsor

Lead sponsor
Azitra Inc.Industry
Sponsor type
Industry
Collaborators
Prosoft Clinical
First posted
Feb 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this randomized clinical trial is to learn if topical treatment with ATR04-484 can treat skin rash in patients undergoing EGFR inhibitor (EGFRi) therapy. The primary goal of the study is to determine safety and tolerability of ATR04-484, and the secondary goal of the study is to assess efficacy signals of ATR04-484. Researchers will compare treatment of ATR04-484 to its vehicle. Participants will: * Apply ATR04-484 or vehicle daily for 28 days * Visit the clinic periodically for evaluation and sample collection

Conditions

  • EGFR Inhibitor-associated Rash

Interventions

  • ATR04-484Drug

    ATR04-484 is a recombinant live biotherapeutic product (rLBP) containing the engineered S. epidermidis strain SE484 in an ointment formulation for topical use

  • VehicleDrug

    Topically applied vehicle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerabilityTime frame: 57 days

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Genesis Cancer and Blood Institute

    Hot Springs, Arkansas · Recruiting

  • Yale University School of Medicine

    New Haven, Connecticut · Recruiting

  • NYU Langone

    New York, New York · Recruiting

  • The Ohio State University

    Gahanna, Ohio · Recruiting

  • MD Anderson

    Houston, Texas · Recruiting

  • Inova Schar Cancer

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.